CBD Life Sciences Inc.
CBDL · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 38% | -23.9% | -61.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | -$0 | $0 |
| % Margin | -78.3% | 39.6% | -71.6% | 40.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -234.9% | -2,948% | -1,941.7% | -172.1% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -234.9% | -2,948% | -1,941.8% | -172.1% |
| EPS | 0 | -0 | -0 | -0 |
| % Growth | 100% | 0% | 0% | – |
| EPS Diluted | 0 | -0 | -0 | -0 |
| Weighted Avg Shares Out | 3,414 | 3,097 | 2,063 | 642 |
| Weighted Avg Shares Out Dil | 3,414 | 3,097 | 2,063 | 642 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -119.1% | -2,948% | -1,820.1% | -124.9% |